Sunesis Pharmaceuticals Inc. (SNSS) was among the biggest gainers on the Russell 2000 for Wednesday January 20 as the stock popped 5.21% to $0.86, representing a gain of $0.0425 per share. Some 205,397 shares traded hands on 343 trades, compared with an average daily volume of 456,282 shares out of a total float of 75.47 million. The stock opened at $0.81 and traded with an intraday range of $0.86 to $0.80.
After today's gains, Sunesis Pharmaceuticals Inc. reached a market cap of $64.77 million. Sunesis Pharmaceuticals Inc. has had a trading range between $3.72 and $0.74 over the last year, and it had a 50-day SMA of $0.88 and a 200-day SMA of $1.66.
Sunesis Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers.
Sunesis Pharmaceuticals Inc. is based out of South San Francisco, CA and has some 39 employees. Its CEO is Daniel N. Swisher.
For a complete fundamental analysis analysis of Sunesis Pharmaceuticals Inc., check out Equities.com’s Stock Valuation Analysis report for SNSS. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.
The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.